Glycine betaine and its use

Details Glycine betaine and its use Glycine betaine and its use

2003-08-04

2009-10-27

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S165000, C424S400000, C424S422000

Reexamination Certificate

active

07608640

ABSTRACT:
The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

REFERENCES:
patent: 4066756 (1978-01-01), Orr et al.
patent: 4605548 (1986-08-01), Ushiyama et al.
patent: 4703045 (1987-10-01), Guinot
patent: 4911916 (1990-03-01), Cleary
patent: 5405614 (1995-04-01), D'Angelo et al.
patent: 5716941 (1998-02-01), Rabinoff
patent: 5814599 (1998-09-01), Mitragotri et al.
patent: 5876780 (1999-03-01), Vertanen et al.
patent: 5880098 (1999-03-01), Häussinger
patent: 5928195 (1999-07-01), Malamud et al.
patent: 5961999 (1999-10-01), Bimczok et al.
patent: 6235311 (2001-05-01), Ullah et al.
patent: 6287765 (2001-09-01), Cubicciotti
patent: 6355166 (2002-03-01), Amarasinghe et al.
patent: 6399785 (2002-06-01), Murphy et al.
patent: 6476006 (2002-11-01), Flashner-Barak et al.
patent: 6855734 (2005-02-01), Messadek
patent: 2002/0034757 (2002-03-01), Cubicciotti
patent: 2002/0065320 (2002-05-01), Messadek
patent: 2002/0183380 (2002-12-01), Hunter
patent: 2006/0233877 (2006-10-01), Messadek et al.
patent: 1012546 (2000-12-01), None
patent: 09900164 (2000-12-01), None
patent: 1012712 (2001-02-01), None
patent: 2003/0248 (2003-04-01), None
patent: 19910682 (2000-09-01), None
patent: 0347864 (1989-06-01), None
patent: 0349902 (1989-06-01), None
patent: 0781554 (1996-07-01), None
patent: 2590 (1963-03-01), None
patent: 2590 (1964-06-01), None
patent: 70.47549 (1970-12-01), None
patent: 77 29075 (1977-09-01), None
patent: 210122 (1992-09-01), None
patent: 10321984 (1998-12-01), None
patent: 2000-143486 (2000-05-01), None
patent: 9515750 (1993-12-01), None
patent: 9738685 (1996-04-01), None
patent: 9819690 (1996-11-01), None
patent: 9706795 (1997-02-01), None
patent: WO 97/38686 (1997-10-01), None
patent: WO 98/56497 (1998-12-01), None
patent: WO 99/45913 (1999-09-01), None
patent: 0025764 (2000-05-01), None
patent: 0051596 (2000-09-01), None
patent: WO 01/56609 (2001-08-01), None
patent: WO 02/00213 (2002-01-01), None
patent: WO 02/47493 (2002-06-01), None
patent: WO 02/062322 (2002-08-01), None
patent: WO 02/066002 (2002-08-01), None
patent: WO 2004/032916 (2004-04-01), None
patent: WO 2004/049095 (2004-06-01), None
Savi et al.; Article from Entrez-PubMed web page entitled: SR 121787, a new orally active fibrinogen receptor antagonist; Sep, 80(3):469-76.
Banno et al.; Article from Entrez-PubMed web page entitled: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist; Eur J Pharmacol Feb. 19, 1999; 367 (2-3): 275-82.
Ramjit et al.; Article from Entrez-PubMed web page entitled: Antithrombotic effects of MK-0852, a platelet fibrinogent receptor antagonist, in canine models of thrombosis; J Pharmacol Exp Ther Sep. 1993; 266(3): 1501-11.
Savi et al.; Article from Entrez-PubMed7.htm web page entitled: SR121787, a new orally active fibrinogen receptor antagonist.; Thromb Haemost Sep. 1998; 80(3): 469-76.
Hoffmann et al.; Article from Entrez-PubMed web page entitled: SR 121787, Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagnoist; J Pharmacol Exp Ther Aug. 1998; 286(2): 670-5.
Packham; Article from Entrez-PubMed web page entitled: Role of platelets in thrombosis and hemostasis; Can J Physiol Pharmacol Mar. 1994; 72(3): 278-84.
Lynch et al.; Article from Entrez-PubMed web page entitled: Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383; J Pharmacol Exp Ther Jan. 1995; 272(1): 20-32.
Kathda et. al.; Articl from Entrez-PubMed web page entitled: The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403, (1997).
Article from Entrez-PubMed web page entitled: antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs, Ogawa et al. (Mar. 2002).
XP-002123170; Database Chemabs ′Online!; Chemical Abstracts Service, Columbus, OH; Zapadnyuk, B.I. et al.: “Bile-secretory effect of trimethylglycine in normal and atherosclerotic animals of different ages” retrieved from STN Databas accession No. 107:190742 HCA; abstract & Byull. Eksp. Biol. Med. (1987), 104(7), 30-2.
XP002123171; Database Chembas ′Online!; Chemical ABstracts Service, Columbus, OH: Panteleimonova, T.N. et al.: “Effect of trimethylglycine on lipid metabolism in rabbits with experimental atherosclerosis” retrieved from STN; Database accession No. 99:99080 HCA; abstract & Farmakol. Toksikol. (Moscow) (1983), 46(4), 83-5.
XP-000853747; Fazio B Et al: “Treatment of human atherosclerosis with betaine.” Minerva Med, (Apr. 25, 1961) 52 1511-6., the whole document.
XP-002123167; P.H. List et al.: “Hagers Handbuch Der Pharmazeutischen Praxis” 1972, Springer-Verlag, Berlin Heidelberg, New York, p. 431.
XP000853853; “Betaine for homocystinuria.” Medical Letter on Drugs and Therapeutics, (1997); 39/993 (12)., the whole document.
XP000853897; Wilcken D E et al: “The natural history of vascular disease in homocystinuria and the effects of treatment.” Journal of Inherited Metabolic Disease, (Jun. 1997) 20 (2) 295-300., the whole document.
XP-002123168; J.E.F. Reynolds: “Martindale, The Extra Pharmacopoeia”;1996, Royal Pharmaceutical Society, London;“Betaine hydrochloride”; p. 1679.
XP002123169; “the merck index”; 1996, Merck & Co, Whithouse Stations, NJ; “Betaine”; p. 198.
Mar at al.; Betaine in wine: answer to the French paradox?; Med Hypothese Nov. 1999; 53(5):383-5.
Salamone et al.; Changes in blood coagulation in experimental subacute poisoning with p-dichlorobenzene. The influence of some lipotropic factors; Journal; Answer 13 of 13; Copyright 2003.
XP001080754; Vinson et al.; New Dug Approvals of 1996—Part 3; University of Mississippi School of Pharmacy; Drug Topics; Mar. 17, 1997; pp. 72-81.
XP-002202249;Napreben;Pharmaprojects; Applied Pharma Research; Company communication, APR, Sep. 1995; whole document.
Matthews et al.; An indirect response model for homecysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria; copyright 2002 Blackwell Science Ltd. Br J Clin Pharmacol, 54, 140-146.
Schwahn et al.; Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria; copyright 2003 Blackwell Science Ltd. Br J Clin Pharmacol, 55, 6-13.
Bandfield et al.; Naproxen, Naproxen Sodium, and Naproxen Betainate Sodium Monohydrate Salts; Pharmaceutics I; Apr. 14, 2001; 5 pages.
van Hecken et al.; Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers; Drug Metabol Drug Interact 1998; 14 (3): 193-205.
Rogers J.S., “Hypercoagulable states,” W V Med J., Feb. 1993;89(2):61-3, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermTo....
Nielsen H.K., “Pathophysiology of venous thromboembolism,” Semin Thromb Hemost, 1991;17 Suppl 3:250-3, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermTo....
Silver et al., “The caput medusae of hypercoagulability,” J. Vasc. Surg., Feb. 2000;31(2):396-405, http://www.ncbi.nom.nih.gov/sites/entrez.
Carman and Fernandez, “A Primary Care Approach to the Patient with Claudication,” American Family Physician, vol. 61, No. 4, Feb. 15, 2000, http://www.aafp.org/afp/20000215/1027.html, 8 pages.
Beaufour and Beaufour, “Nouvelles associations antinévralgiques à tolérance améliorée,” Brevet Spécial De Médicament, P.V. No. 927.734, No. 2.590, 1964, pp. 1-5.
Feb. 23, 1996 Chinese document (pp. 91-93) with English translation entitled “Homocysteine and Vascular Disease,” 5 pages.
Da Silva and Sobel, “Anicoagulants: to bleed or not to bleed, that is the question,

Affiliated with

Also associated with

Rating

Glycine betaine and its use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycine betaine and its use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycine betaine and its use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4106273